ArticleFrontiers in gastroenterology (Lausanne, Switzerland)2025
Case Report: jaundice in the young: the complexity of rare diseases beyond cholangiopathies.
Article in Frontiers in gastroenterology (Lausanne, Switzerland), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Jaundice is a common presentation of diseases of the biliary tree, which differential diagnosis can be challenging, in particular when associated to pancreas involvement. In this respect, autoimmune pancreatitis (AIP), a rare form of chronic pancreatitis, shares clinical presentations with pancreatic cancer, such as biliary obstruction and pancreatic mass. AIP is categorized into two subtypes, type 1, associated with elevated serum IgG4 levels and systemic involvement, including the biliary system, and type 2, which is not linked to IgG4 and can be associated with inflammatory bowel disease (IBD). Early recognition is critical as both subtypes respond well to corticosteroid therapy, potentially avoiding unnecessary surgical interventions. Here we discuss the case of a 29-year-old African man with no significant medical history, who presented with skin-scleral jaundice, pale stools, dark urine, and mild weight loss. Laboratory results showed elevated liver and pancreatic enzymes, and imaging revealed bile duct dilation and pancreatic enlargement, raising suspicion of AIP. Serum IgG4 levels were normal, and fecal calprotectin was elevated, suggesting possible IBD. Corticosteroid therapy was initiated, leading to rapid remission of jaundice. One year later, the patient developed gastrointestinal symptoms, mostly abdominal pain and diarrhea, which led to the endoscopic diagnosis of Crohn's disease. This association further supported the diagnosis of type 2 AIP. The patient subsequently developed a recurrent jaundice due to autoimmune hemolytic anemia (AHIA), a very rare complication of AIP, supported by a positive Coombs test. Once again, corticosteroids resulted in a complete clinical response. This case illustrates the diagnostic challenges of jaundice caused by pancreato-biliary diseases and the wide range of related immunological disorders, i.e. IBD and AHIA, which may influence the clinical presentation. Prompt recognition of the disease enables us to start timely corticosteroid therapy, which confirmed the diagnosis avoiding unnecessary surgery.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.